Regeneron
·
Oncology / Dermatology
·
Social HCP Targeting
Libtayo Portfolio
Meta + LinkedIn · cSCC · BCC · NSCLC
Results at a Glance
Libtayo Portfolio · EQ5-1342 + EQ5-1343
90%
NPI Match Rate
Industry avg: 40–60%
757K
Total Impressions
697,276 identified · all programs
20,549
Unique HCPs Reached
Portfolio total · all programs
0.27%
Campaign CTR
0.67% top creative · 0.35% current best
36×
Avg HCP Frequency
per exposed HCP
LinkedIn
316K impressions · 1,139 clicks · 0.38% CTR · Strongest HCP engagement
Impression Split
Meta · 441K impressions · 58%
LinkedIn · 316K impressions · 42%
757K total · LinkedIn delivers 2× higher CTR at 42% of impressions
Executive Snapshot
EQ5 Account Snapshot · Regeneron Libtayo · May 2026
May 7, 2026
Equals 5 is the NPI-matched HCP targeting platform powering Regeneron’s Libtayo social media program — reaching dermatologists, oncologists, and pulmonologists on Meta and LinkedIn with physician-level precision and monthly NPI engagement reports.
3
Libtayo Programs
EQ5-1123 + 1314 + 1342 + 1343
EQ5-1123 + 1314 + 1342 + 1343
2
Active In Flight
Libtayo Skin & Lung 2026
Libtayo Skin & Lung 2026
81–90%
NPI Match Rate Range
5 cohorts · vs. 40–60% industry avg
5 cohorts · vs. 40–60% industry avg
0.27%
Campaign CTR
Libtayo Skin Pilot · EQ5-1123
Libtayo Skin Pilot · EQ5-1123
What EQ5 Does
Regeneron / CMI provides the Libtayo NPI target list. Equals 5 matches each NPI through our proprietary Personi 5™ datagraph (2.2M verified HCPs) and activates physician-targeted ads on Meta (Facebook/Instagram) and LinkedIn. Every impression and click is reported back at the NPI level — so Regeneron sees exactly which dermatologists and oncologists engaged with Libtayo content, on which channel, and how many times. No modeled audiences. No guesswork.
Why It Matters for Libtayo
The Libtayo Skin pilot (EQ5-1123) delivered 100% of booked impressions and reached 79% of dermatology and oncology targets — validating the model across cSCC and BCC. That proof directly funded two 2026 programs: Libtayo Skin (EQ5-1342, in monitoring) and Libtayo Lung (EQ5-1343, now live May 2026). Both run on the same deterministic NPI-matching platform with Meta + LinkedIn Newsfeed delivery, building on pilot audience insights.
Active Programs
Cutaneous Squamous Cell Carcinoma (cSCC) & Basal Cell Carcinoma (BCC) · Meta + LinkedIn Newsfeed
Channels:
Meta (Facebook / Instagram) · LinkedIn Newsfeed · Dermatologists · Mohs Surgeons · cSCC + BCC
Non-Small Cell Lung Cancer (NSCLC) · Meta + LinkedIn Newsfeed
Channels:
Meta + LinkedIn Newsfeed · NPI reports weekly Wednesdays via CMI SFTP · LinkedIn R1 + Meta active
⚠ Pacing: LinkedIn R1 −83% Critical · Meta −35% Critical · Creative optimization in progress
Audience Architecture
Total NPIs Uploaded
122,800
5 cohorts · Skin + Lung + Sub-cohorts
NPI Matched
63,113
81.7% avg match · vs. 40–60% industry
Unique HCPs Reached
20,549
Portfolio total · all programs to date
NPI Match Rate by Program
EQ5 deterministic matching vs. industry average (40–60%)
Channels
Meta — Facebook / Instagram
Volume reach driver
Broad HCP awareness · All specialist segments · Highest impression volume
LinkedIn Newsfeed
Professional engagement
Strongest HCP CTR (0.38%) · Derm + Oncology + Pulmonology KOLs
Personi 5™ Datagraph
Matching infrastructure
2.2M verified HCPs · Deterministic NPI matching · No modeled audiences
Measurement & Reporting
Impressions by Channel
All 2026 programs
CTR by Channel
Click-through rate · LinkedIn leads
Program Timeline
All Programs · Libtayo Portfolio
Libtayo Skin 2026 · EQ5-1342
Monitoring
Mar 2026 – Dec 2026 · Meta + LinkedIn Newsfeed · 90% NPI match · 0.29% CTR
Libtayo Lung 2026 · EQ5-1343
Active
2026 · Flight 2 live May 2026 · LinkedIn R1 + Meta running · 49,056 impressions delivered
Libtayo Skin Pilot · EQ5-1123 + EQ5-1314
Complete
Oct 2025 – Feb 2026 · 594K impressions · 0.27% CTR · Final report Apr 10, 2026
Client
Regeneron
Agency
CMI Media Group
Status
Active
Therapeutic Focus
cSCC · BCC · NSCLC